Publications by authors named "Mark Jeffery"

Claim this Profile
A
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial.
John W K Chia, Eva Segelov, Yanhong Deng, Gwo Fuang Ho, Wei Wang, Mark G Jeffery

Lancet Gastroenterol Hepatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer.
Di Maria Jiang, Shruti Parshad, Luna Zhan, Hao-Wen Sim, Lillian L Siu, Mark Jeffery

Clin Colorectal Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of burnout on empathy.
Molly Reynolds, Andrew McCombie, Mark Jeffery, Roger Mulder, Frank Frizelle

N Z Med J· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionation for clinically localized prostate cancer.
Brigid E Hickey, Melissa L James, Tiffany Daly, Feng-Yi Soh, Mark Jeffery

Cochrane Database Syst Rev· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up strategies for patients treated for non-metastatic colorectal cancer.
Mark Jeffery, Brigid E Hickey, Phillip N Hider

Cochrane Database Syst Rev· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand-INSIGHT.
Yeojeong Jane So, Michael Jameson, Vincent Newton, Anne O'Donnell, Mark Jeffery

N Z Med J· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The New Zealand PIPER Project: colorectal cancer survival according to rurality, ethnicity and socioeconomic deprivation-results from a retrospective cohort study.
Katrina J Sharples, Melissa J Firth, Victoria A Hinder, Andrew G Hill, Mark Jeffery

N Z Med J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line Wild-Type Metastatic Colorectal Cancer.
Andrew G Hill, Michael P Findlay, Matthew E Burge, Christopher Jackson, Pilar Garcia Alfonso, Mark Jeffery

Clin Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up strategies for patients treated for non-metastatic colorectal cancer.
Mark Jeffery, Brigid E Hickey, Phil N Hider, Adrienne M See

Cochrane Database Syst Rev· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods of a national colorectal cancer cohort study: the PIPER Project.
Melissa J Firth, Katrina J Sharples, Victoria A Hinder, Jerome Macapagal, Diana Sarfati, Mark Jeffery

N Z Med J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fraction size in radiation therapy for breast conservation in early breast cancer.
Brigid E Hickey, Melissa L James, Margot Lehman, Phil N Hider, Mark Jeffery

Cochrane Database Syst Rev· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A Sullivan, G Mark Jeffery

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Let the sunshine in--making industry payments to New Zealand doctors transparent.
Cindy Farquhar, Tim Stokes, Andrew Grey, Mark Jeffery, Peter Griffin

N Z Med J· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Jolie Ringash, Heather-Jane Au, Lillian L Siu, Jeremy D Shapiro, Derek J Jonker, Mark Jeffery

Cancer· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of guidance for the management of early bowel cancer.
Anita Fitzgerald, Frank Frizelle, Mark Jeffery, Adrian Balasingam, Jan Casey

N Z Med J· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fraction size in radiation treatment for breast conservation in early breast cancer.
Melissa L James, Margot Lehman, Phil N Hider, Mark Jeffery, Brigid E Hickey

Cochrane Database Syst Rev· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
Michael B Jameson, Dianne M Sharp, Jennifer I Sissingh, Christopher R Hogg, Paul I Thompson, Mark Jeffery

Invest Ophthalmol Vis Sci· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fraction size in radiation treatment for breast conservation in early breast cancer.
Melissa L James, Margot Lehman, Phil N Hider, Mark Jeffery, Daniel P Francis

Cochrane Database Syst Rev· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Charles S Fuchs, John Marshall, Edith Mitchell, Rafal Wierzbicki, Vinod Ganju, Mark Jeffery

J Clin Oncol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Mark J McKeage, Peter Fong, Mark Jeffery, Bruce C Baguley, Phil Kestell

Clin Cancer Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Degradation kinetics of VX on concrete by secondary ion mass spectrometry.
John M Williams, Brad Rowland, Mark T Jeffery, Gary S Groenewold, Anthony D Appelhans

Langmuir· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postoperative follow-up strategies for patients after potentially curative surgery for colorectal cancer at Christchurch Hospital.
Hayley Simpson, Mark Jeffery, Brigid Hickey, Frank Frizelle, Chris Frampton

N Z Med J· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in the pathology reporting of rectal cancer: is it time to adopt synoptic reporting?
Chris Hemmings, Mark Jeffery, Frank Frizelle

N Z Med J· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrolysis of VX on concrete: rate of degradation by direct surface interrogation using an ion trap secondary ion mass spectrometer.
Gary S Groenewold, John M Williams, Anthony D Appelhans, Garold L Gresham, John E Olson, Mark T Jeffery

Environ Sci Technol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis